Evidence map›Paper›PMID 34741525›Full record

ArticleFEBS letters2021

Inhibition of the futalosine pathway for menaquinone biosynthesis suppresses Chlamydia trachomatis infection.

Brianne M Dudiak, Tri M Nguyen, David Needham, Taylor C Outlaw, Dewey G McCafferty

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Brianne M DudiakDepartment of Chemistry, Duke University, Durham, NC, USA.ORCID 0000-0001-7229-9644
Tri M NguyenDepartment of Chemistry, Duke University, Durham, NC, USA.
David NeedhamDepartment of Mechanical Engineering and Materials Science, Duke University, Durham, NC, USA.
Taylor C OutlawDepartment of Chemistry, Duke University, Durham, NC, USA.
Dewey G McCaffertyDepartment of Chemistry, Duke University, Durham, NC, USA.ORCID 0000-0002-3253-9233
Duke University · US

Funding

Pharmacological Sciences Training ProgramT32GM007105 · NIGMS · DUKE UNIVERSITY · PI KUHN, CYNTHIA M · 1985 to 2019
$9.0M
Pharmacological Sciences Training ProgramT32GM133352 · NIGMS · DUKE UNIVERSITY · PI Cynthia M Kuhn, David M MacAlpine · 2020 to 2026
$3.8M
NIGMS NIH HHS T32 GM007105NIGMS NIH HHS T32 GM133352
6 · The paper itself

Abstract

Chlamydia trachomatis, an obligate intracellular bacterium with limited metabolic capabilities, possesses the futalosine pathway for menaquinone biosynthesis. Futalosine pathway enzymes have promise as narrow-spectrum antibiotic targets, but the activity and essentiality of chlamydial menaquinone biosynthesis have yet to be established. In this work, menaquinone-7 (MK-7) was identified as a C. trachomatis-produced quinone through liquid chromatography-tandem mass spectrometry. An immunofluorescence-based assay revealed that treatment of C. trachomatis-infected HeLa cells with the futalosine pathway inhibitor docosahexaenoic acid (DHA) reduced inclusion number, inclusion size, and infectious progeny. Supplementation with MK-7 nanoparticles rescued the effect of DHA on inclusion number, indicating that the futalosine pathway is a target of DHA in this system. These results open the door for menaquinone biosynthesis inhibitors to be pursued in antichlamydial development.

Indexed as

Biosynthetic PathwaysAnti-Bacterial AgentsAutomationChlamydia InfectionsChlamydia trachomatisDocosahexaenoic AcidsHeLa CellsHumansInclusion BodiesNanoparticlesNucleosidesVitamin K 2Anti-Bacterial AgentsDocosahexaenoic Acidsfutalosinemenaquinone 7NucleosidesVitamin K 2Chlamydia trachomatisdocosahexaenoic acidfutalosine pathwaymenaquinone

Identifiers

PMID34741525
PMCPMC9980418
OpenAlexW3208881272

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.